Business, energy, technology, markets and global industry news from Business News Today

non-muscle-invasive bladder cancer

PharmaDeviceNews non-muscle-invasive bladder cancer
Representative image: AstraZeneca’s Imfinzi approval with BCG brings immunotherapy into earlier bladder cancer care, reshaping treatment options for high-risk non-muscle-invasive bladder cancer.
Pharma & Biotech

FDA expands ANKTIVA approval to papillary-only bladder cancer after BCG failure

The FDA has expanded ANKTIVA plus BCG to adults with BCG-unresponsive high-grade papillary-only non-muscle-invasive bladder cancer. The decision relies on existing clinical evidence and biological similarities with carcinoma in situ, rather than a new pivotal efficacy result specifically demonstrating treatment benefit in papillary-only patients.

Read More
Pharma & Biotech

AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer

Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.

Read More
Representative image: AstraZeneca’s Imfinzi approval with BCG brings immunotherapy into earlier bladder cancer care, reshaping treatment options for high-risk non-muscle-invasive bladder cancer.
Pharma & Biotech

Imfinzi approval gives AstraZeneca a first immunotherapy combination in early bladder cancer

Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?

Read More
Representative image of an oncology researcher reviewing bladder cancer treatment data, as ImmunityBio’s ANKTIVA plus BCG analysis raises new questions about cost, response durability and bladder-sparing care in BCG-unresponsive NMIBC.
Pharma & Biotech

Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate

Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.

Read More